BridgeBio Pharma Inc (BBIO)
25.61
+0.13
(+0.51%)
USD |
NASDAQ |
Nov 04, 13:09
BridgeBio Pharma Enterprise Value: 6.072B for Nov. 1, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 01, 2024 | 6.072B |
| October 31, 2024 | 5.683B |
| October 30, 2024 | 5.754B |
| October 29, 2024 | 5.887B |
| October 28, 2024 | 5.876B |
| October 25, 2024 | 5.763B |
| October 24, 2024 | 5.825B |
| October 23, 2024 | 5.878B |
| October 22, 2024 | 5.970B |
| October 21, 2024 | 6.012B |
| October 18, 2024 | 6.173B |
| October 17, 2024 | 6.205B |
| October 16, 2024 | 6.233B |
| October 15, 2024 | 6.053B |
| October 14, 2024 | 6.128B |
| October 11, 2024 | 6.151B |
| October 10, 2024 | 5.974B |
| October 09, 2024 | 5.677B |
| October 08, 2024 | 5.931B |
| October 07, 2024 | 5.951B |
| October 04, 2024 | 6.025B |
| October 03, 2024 | 6.100B |
| October 02, 2024 | 5.997B |
| October 01, 2024 | 5.944B |
| September 30, 2024 | 6.068B |
| Date | Value |
|---|---|
| September 27, 2024 | 5.970B |
| September 26, 2024 | 5.884B |
| September 25, 2024 | 5.889B |
| September 24, 2024 | 5.955B |
| September 23, 2024 | 6.057B |
| September 20, 2024 | 6.309B |
| September 19, 2024 | 6.326B |
| September 18, 2024 | 6.162B |
| September 17, 2024 | 6.307B |
| September 16, 2024 | 6.205B |
| September 13, 2024 | 6.203B |
| September 12, 2024 | 6.348B |
| September 11, 2024 | 6.544B |
| September 10, 2024 | 6.920B |
| September 09, 2024 | 7.053B |
| September 06, 2024 | 7.053B |
| September 05, 2024 | 7.166B |
| September 04, 2024 | 7.048B |
| September 03, 2024 | 6.685B |
| August 30, 2024 | 6.517B |
| August 29, 2024 | 5.910B |
| August 28, 2024 | 5.963B |
| August 27, 2024 | 5.978B |
| August 26, 2024 | 6.151B |
| August 23, 2024 | 6.040B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
1.607B
Minimum
Mar 18 2020
10.69B
Maximum
Feb 08 2021
5.155B
Average
4.687B
Median
Oct 13 2020
Enterprise Value Benchmarks
| Alnylam Pharmaceuticals Inc | 33.57B |
| Pfizer Inc | 221.03B |
| Vertex Pharmaceuticals Inc | 115.80B |
| PTC Therapeutics Inc | 2.305B |
| Bristol-Myers Squibb Co | 151.89B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -73.46M |
| Revenue (Quarterly) | 2.168M |
| Total Expenses (Quarterly) | 174.82M |
| EPS Diluted (Quarterly) | -0.39 |
| Gross Profit Margin (Quarterly) | 72.42% |
| Profit Margin (Quarterly) | -3.39K% |
| Earnings Yield | -10.27% |
| Normalized Earnings Yield | -12.49 |